AWM
PTCT icon

Abound Wealth Management’s PTC Therapeutics PTCT Stock Holding History

Abound Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164 Sell
2
-2
-50% -$144 ﹤0.01% 1164
2026
Q1 		$273 Hold
4
– – ﹤0.01% 1147
2025
Q4 		$304 Buy
+4
New +$291 ﹤0.01% 1041

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Abound Wealth Management's PTCT Position: Q2 2026 in Review

Abound Wealth Management reduced its PTC Therapeutics (PTCT) stake by 50% in Q2 2026, selling an estimated $144 and leaving 2 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #1164.

Abound Wealth Management first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $304 in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Abound Wealth Management held 2 shares of PTC Therapeutics worth $164 as of Q2 2026.
  • Abound Wealth Management sold 2 PTC Therapeutics shares in Q2 2026, an estimated $144.
  • PTC Therapeutics made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1164 holding.
  • Abound Wealth Management first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Abound Wealth Management's PTC Therapeutics position peaked at $304 in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.